翰宇药业: 2024年年度业绩快报

Financial Performance Summary - The total operating revenue for 2024 reached 590.20 million yuan, representing a year-on-year increase of 36.82% compared to 431.38 million yuan in the previous year [1] - Operating loss significantly narrowed to -168.02 million yuan, an improvement of 66.89% from -507.50 million yuan in the prior year [1] - Total profit also improved to -169.04 million yuan, reflecting a 66.93% reduction from -511.10 million yuan [1] - The net profit attributable to shareholders of the listed company was -180.42 million yuan, a 64.89% improvement from -513.88 million yuan [1] - The basic earnings per share improved to -0.20 yuan, a 65.52% increase from -0.58 yuan [1] - The weighted average return on net assets improved to -27.25%, a 23.39% increase from -50.64% [1] Business Operations and Growth Factors - The overseas business continued to grow, with peptide formulations and raw material drug sales driving overall revenue growth [2] - Changes in revenue structure led to an increase in operating profit margins, as the previous year was dominated by domestic business with lower profit margins [2] - The company enhanced operational efficiency, resulting in a reduction in expense ratios [2] Financial Position - Total assets at the end of the reporting period were 3,001.59 million yuan, down 8.41% from 3,277.19 million yuan at the beginning of the period [1] - The equity attributable to shareholders of the listed company decreased by 24.64% to 571.86 million yuan from 758.80 million yuan [1]